Lupin reports Q1 FY2025 results with strong sales growth
after close1 source ↓written by the desknot a recommendation
- marking
- 28.3% YoY increase
- from the U.S
- 6 ANDA approvals
- this quarter
- 3 new products
- player
- 3rd largest
Lupin Limited reported its Q1 FY2025 results, with North America sales at ₹20,408 Mn, marking a 28.3% YoY increase. The U.S. sales reached USD 227 Mn, up from USD 181 Mn in Q1 FY2024. The company received 6 ANDA approvals from the U.S. FDA and launched 3 new products this quarter.
This performance solidifies Lupin's position as the 3rd largest player in the U.S. generics market, which may enhance investor sentiment and trading activity in the pharmaceutical sector.
Not investment advice. For informational purposes only.